Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus

NCT02220920 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.

NCT NCT02220920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02220920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Tanabe Pharma Corporation
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2014
Completion date
July 31, 2015
Enrollment
146 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus